The mysteries of inflammatory bowel disease are being cracked — offering hope for new therapies - Cooperative Research Centre for Developing Northern Australia

Summary

This article explores several recent scientific advances that are improving understanding of inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis. It highlights new research showing how genetic factors, immune system dysfunction and changes in the gut microbiome may contribute to disease development and progression.

The article focuses on three key discoveries: the identification of a genetic regulator (ETS2) linked to inflammation, evidence that some patients produce antibodies that block the anti-inflammatory protein IL-10, and research showing how gut bacteria adapt to inflamed environments. Together, these findings could help clinicians better classify patients and match them with more effective, personalised treatments.

While the research is still at an early stage, the article notes that these discoveries offer new pathways for developing targeted therapies and improving outcomes for people living with IBD. It also highlights the growing need for better treatments as the prevalence of IBD continues to rise globally.

This article provides useful context for emerging biotechnology approaches, including the development of novel immune-modulating therapies such as those being pursued by Macrobiome Therapeutics.

Novel therapeutics for diabetes sourced from Northern Australian biota

This project explored the potential of hookworm-derived molecules as a new class of biologic therapies for chronic disease. Building on evidence that hookworms can regulate immune responses and reduce inflammation, researchers identified and tested proteins produced by hookworms native to northern Australia as potential treatments for Type 2 diabetes. The project combined drug discovery, laboratory research and preclinical testing to identify the most promising therapeutic candidates and evaluate their safety, effectiveness and suitability for further development. Using advanced research facilities at James Cook University, the team generated new knowledge about the therapeutic potential of worm-derived molecules and their role in treating metabolic and inflammatory diseases. While the project initially focused on Type 2 diabetes, changing market conditions and the emergence of new diabetes treatments led Macrobiome Therapeutics to apply the platform to inflammatory bowel disease (IBD), where the underlying science showed strong potential. The research helped secure $2.8 million in follow-on private investment, enabling continued development of the technology and supporting the growth of a biotechnology company based in northern Australia. The project also contributed to regional workforce development, supporting skilled research and technical jobs and strengthening northern Australia’s capability in biologics, immunology and biomedical innovation. By demonstrating how the region’s unique biodiversity can be translated into high-value health technologies, the project has helped lay the foundations for a growing biotechnology sector in northern Australia.